T Cell Immunotherapy Articles & Analysis
9 articles found
This heightened expression of CD19 makes it a valuable target for treating these diseases. CAR-T cell therapy, an immunotherapy, has demonstrated efficacy in treating B-cell lymphoma by genetically modifying the patient's T cells to carry CD19-specific receptors. ...
CAR T Cell Therapy CAR T cell therapy is another immunotherapy utilizing cytotoxic T cells. ...
Chimeric antigen receptor T cells (CAR-T) and T cell antigen receptor chimeric T cells (TCR-T) are currently the "top stream" in adoptive T cell tumor immunotherapy. ...
Researchers at Massachusetts General Hospital (MGH) have found that interferon gamma receptor (IFNgR) signaling is essential for the susceptibility of CAR-T cell immunotherapy to kill malignant gliomas. The same phenomenon has been observed in other solid tumors. ...
Chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) are the main adoptive immunotherapies in recent years. ...
Targeting T cells in T1D CD4+ and CD8+ T cells orchestrate the inflammatory process that ultimately destroys islet β cells and leads to the development of T1D. ...
Immunotherapy, in addition to surgery, chemotherapy, and radiotherapy, has now become the fourth pillar of anticancer treatment, with T cell-based immunotherapy being a successful cancer treatment technique. ...
Using the power of large data and advanced computational methods, researchers can identify peptides on the surface of tumor cells and can target "peptide-centric" chimeric antigen receptors (PC-CARs): a new design of T cells that stimulates the immune response to eliminate tumors. ...
Recently, researchers at Notre Dame University have identified specific features of the reaction of two distinct peptide antigens to a T-cell receptor (TCR), which provides new clues to optimizing molecular structure for the development of immunotherapy of cancer cell research. ...